- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2019-08-25
2024-07-25
2025-07-25
180
NCT04066322
Fudan University
Fudan University
OBSERVATIONAL
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment
This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.
system treatments of metastatic PanNET include SSA, sunitinib, mTOR inhibitor and chemotherapy. For patients achieved PR/SD after system treatment, resection of primary tumor and metastasis maybe a better way to decline tumor burden and get longer survival. this real world study is focused on this group of patients with metastatic PanNET, and to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2019-08-21 | N/A | 2019-09-22 |
2019-08-21 | N/A | 2019-09-24 |
2019-08-26 | N/A | 2019-09 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : system treatment Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy. | PROCEDURE: system treatment and surgery
OTHER: system treatment
|
| : system treatment and Surgery Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision. | PROCEDURE: system treatment and surgery
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| progression-free survival | 5 years |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| overall survival | 5 years | |
| Number of Postoperative morbidity | Including pancreatic fistula, biliary fistula, hemorrhage, wound infection, delayed gastric emptying, reoperation | Up to 90 days after operation |
| number of Postoperative mortality | Up to 90 days after operation |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: xianjun yu, MD Phone Number: +86 21 64175590 Email: yuxianjun@fudanpci.org |
Study Contact Backup Name: Heli Gao Phone Number: +86 21 64175590 Email: gaoheli@fudanpci.org |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
